- Home
- QURE vs XOMA Comparison
QURE vs XOMA Comparison
Compare QURE & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- XOMA
- Stock Information
- Founded
- QURE 1998
- XOMA 1981
- Country
- QURE Netherlands
- XOMA United States
- Employees
- QURE N/A
- XOMA N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- XOMA Health Care
- Exchange
- QURE Nasdaq
- XOMA Nasdaq
- Market Cap
- QURE 432.6M
- XOMA 355.6M
- IPO Year
- QURE 2007
- XOMA N/A
- Fundamental
- Price
- QURE $5.85
- XOMA $30.07
- Analyst Decision
- QURE Buy
- XOMA Strong Buy
- Analyst Count
- QURE 6
- XOMA 2
- Target Price
- QURE $17.00
- XOMA $78.50
- AVG Volume (30 Days)
- QURE 792.5K
- XOMA 32.1K
- Earning Date
- QURE 11-05-2024
- XOMA 11-07-2024
- Dividend Yield
- QURE N/A
- XOMA N/A
- EPS Growth
- QURE N/A
- XOMA N/A
- EPS
- QURE N/A
- XOMA N/A
- Revenue
- QURE $28,587,000.00
- XOMA $21,606,000.00
- Revenue This Year
- QURE $157.96
- XOMA $488.61
- Revenue Next Year
- QURE N/A
- XOMA $27.42
- P/E Ratio
- QURE N/A
- XOMA N/A
- Revenue Growth
- QURE N/A
- XOMA 389.82
- 52 Week Low
- QURE $3.73
- XOMA $14.33
- 52 Week High
- QURE $11.35
- XOMA $33.78
- Technical
- Relative Strength Index (RSI)
- QURE 43.86
- XOMA 51.23
- Support Level
- QURE $5.50
- XOMA $29.20
- Resistance Level
- QURE $7.96
- XOMA $31.24
- Average True Range (ATR)
- QURE 0.59
- XOMA 1.42
- MACD
- QURE -0.16
- XOMA -0.19
- Stochastic Oscillator
- QURE 18.97
- XOMA 20.90
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.